Preview

Современная ревматология

Расширенный поиск

Варфарин в терапии антифосфолипидного синдрома

https://doi.org/10.14412/1996-7012-2008-469

Полный текст:

Аннотация

Описаны фармакокинетика, фармакодинамика и мониторинг терапии варфарином. Рассмотрены вопросы повышенной чувствительности части пациентов к варфарину, а именно ассоциация избыточной гипокоагуляции с мутациями в гене цитохрома Р450 CYP2C9*2 И CYP2C9*3. Суммированы данные литературы о применении варфарина у больных с антифосфолипидным синдромом (АФС). Представлены данные, касающиеся интенсивности антикоагулянтной терапии при АФС. Приведены рекомендации и комментарии, основанные на собственном опыте ведения больных с АФС.

Литература

1. <div><p>Hughes G.R.V. Trombosis, abortion, cerebral disease and lupus anticoagulant. BMJ 1983; 187: 1088-89.</p><p>Hughes G.R.V., Harris E.N., Charavi A.E. The anti-cardiolipin syndrome. J. Rheumatol 1986; 13: 486-9.</p><p>Насонов Е.Л. Антифосфолипидный синдром: клиническая и иммунологическая характеристика. Клин мед 1989; 1: 5-13.</p><p>Насонов Е.Л. Антифосфолипидный синдром. М.: Литтерра 2004; 379.</p><p>Алекберова З.С., Решетняк Т.М., Кошелева Н.М. и др. Антифосфолипидный синдром при системной красной волчанке: оценка диагностических и классификационных критериев. Клин мед 1996; 6: 39-42.</p><p>Asherson R.A., Baguley E., Hughes G.R.V. Antiphospholipid syndrome: five years follow-up. Ann Rheum Dis 1991; 50: 805-10.</p><p>Myakis S., Lockshin M.D., Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospho-lipid syndrome. J Thromb Haemost 2006; 4: 295-306.</p><p>Wood A. Drug therapy. N Engl J Med 1994; 330: 1287-93.</p><p>Rosove M.H., Brewer PM.C. Antiphospholipid thrombosis: dinical course after the first thrombotic event in 70 patients. Ann Int Med 1992; 117: 303-8.</p><p>Derksen R.H.W.M., de Groot Ph.G., Kater L. et al. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 1993; 52: 689-92.</p><p>Khamashta M.A., Cuadrado M.J., Mujic F et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-7.</p><p>Krnic-Barrie S., O'Connor C.R., Looney S.W et al. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of influencing recurrent thrombosis. Arch Intern Med 1997; 157:2101-08.</p><p>Linkins L.A., Weitz J.I. New anticoagulants. Semin Thromb Hemost 2003; 29: 619-31.</p><p>Лечение оральными антикоагулянтами. Рекомендации Всероссийской ассоциации по изучению тромбозов, геморрагий и патологии сосудов им. А.А. Шмидта - Б.А. Кудряшова. М.: РКИ Соверо пресс 2002; 36 с.</p><p>Лечение оральными антикоагулянтами. Методические рекомендации Всероссийской ассоциации по изучению тромбозов, геморрагий и патологии сосудов им. А.А. Шмидта - Б.А. Кудряшова. Сост. Т.В. Козлова. Под ред. Л.Б. Лазебника и И.Н. Бокарева. М.: Издатель Е.Разумова 2003; 28 с.</p><p>Palkimas M.P, Skinner H.M., Gandhi P.J. et al. Polymorphisms induced sensitivity to warfarin: a review of the literature. Journal of Thrombosis and Thrombolysis 2003; 15: 205-12.</p><p>Aithal G.P., Day C.P., Kesteven P.J. et al. Association of polymorphisms in cytochrome P450 CYP2C9 withwarfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9.</p><p>Ansell J., Hirsh J., Poller L. et al. The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 204-33.</p><p>Takahashi H., Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001; 40: 587-603</p><p>Hirsh J., Fuster V., Ansell J. et al. American Heart Association/American College of Cardiology Foundation Guide to warfarin therapy . Circulation 2003; 107: 1692-711.</p><p>Wessler S., Gitel S.N. Warfarin: from bedside to bench. N Engl Med 1984; 311: 645-52.</p><p>Zivelin A., Rao L.V., Rapaport S.I. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual pto-coagulant vitamin-K dependent clotting factors. J Clin Invest 1993; 92: 2131-40.</p><p>Patel P., Weitz J., Brooker L.A. et al. Decreased thrombin activity of fibrin clots prepared in cord plasma compared to adult plasma. Pediatr Res 1996; 39: 826-30.</p><p>Esmon C. T. Molecular events that control the protein C anticoagulant pathway. Thromb Haemost 1993; 70: 29-35.</p><p>Weitz J.I., Hudoba M., Massel D. et al. Clot- bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inac-tivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.</p><p>Bajzar L., Manuel R., Nesheim M.E. Purification and characterization of TAFI, a throm-bin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.</p><p>Furie B., Diuguid C.F., Jacobs M. et al. Randomized prospective trial comparing the native pro-thrombin antigen with the prothrombin time for monitoring anticoagulant therapy. Blood 1990; 75: 344-9.</p><p>Moll S., Ortel T.L. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997; 127: 177-85.</p><p>Le D.T., Weibert R.T., Sevilla B.K. et al. The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods. Ann Intern Med 1994; 120: 552-8.</p><p>Lind S.E., Callas P.W., Golden E.A. et al. Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy. Blood Coagul Fibrinolysis 1997; 8: 48-53.</p><p>Kornberg A., Francis C.W., Pellegrini V.D. et al. Comparison of native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant prophylaxis. Circulation 1993; 88: 454-60.</p><p>Kasthuri R.S., Roubey R.A. Warfarin and the antiphospholipid syndrome: does one size fit all? Arthritis Rheum 2007; 57(8, Dec. 15): 1346-47.</p><p>Wells P.S., Holbrook A.M., Crowther N.R. et al. Interactions of warfarin with drugs and food. Ann Intern Med 1994; 121: 676-83.</p><p>Чуваева А.В., Балоян Г.М., Зайтман Е.В. и др. Диета и варфаринотерапия. Тромбоз, гемостаз и реология 2004; 1: 73-74.</p><p>Readman A. Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing. Pharmacotherapy 2001; 21: 235-41.</p><p>Bhasker C.R., Miners J.O., Coulter S. et al. Allelic and functional variability of cytochrome P450 2C9. Pharmacogenetics 1997; 7: 51-8.</p><p>Lee C.R., Goldstein J.A., Pieper J.A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human date. Pharmacogenetics 2002; 12: 251-63.</p><p>Taube J., Halsall D., Baglin T. Influence of cytochrome P450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96: 1816-19.</p><p>Higashi M., Veenstra D., Midori Kondo L. et al. Association between CYP2C9 genetic variants and anticoagulation - related outcomes during warfarin therapy. JAMA 2002; 287: 1690-98.</p><p>Joffe H.V., Xu R., Johnson F.B. et al. Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost 2004; 91: 1123-28.</p><p>Bodin L., Verstuyft C., Tregouet D.A. et al. Cytochrome P4502C9 (CYP2C9) and vitamin K epox- ide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005; 106: 135-40.</p><p>Ruiz-Irastorza G., Hunt B.J., M.A.Khamashta. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 2007; 57(8, Dec.15): 1487-95.</p><p>Munoz-Rodriguez F.J. Font J. Cervera et al. Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum 1999; 29: 182-90.</p><p>Ruiz-Irastorza G., Khamashta K.A., Hunt B.J. et al. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: an analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3,5. Arch Intern Med 2002; 162: 1164-9.</p><p>Witkowsky A.K., Downing J., Blackburn J. et al. Warfarin-related outcomes in patients with antiphos-pholipid antibody syndrome managed in an anticoagulation clinic. Thromb Haemost 2006; 96: 137-141.</p><p>Parandoni P., Simioni P., Girolami A. Antiphospholipid antibodies, recurrent thromboem-bolism, and intensity of warfarin anticoagulation [letter]. Thromb Haemost 1996;75:859.</p><p>Rance A., Emmerich J., Fiessinger J.N. Anticardiolipin antibodies and recurrent thromboembolism [letter]. Thromb Haemost 1997; 77:221-2.</p><p>Levine S.R., Brey R.L., Tilley B.C. et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291: 576-84.</p><p>Levine M.N., Rascobe G., Landefeld S. et al. Hemorrhagic complications of anticoagulant treatment. Chest 2001;119: 108-21.</p><p>Brey R.L., Levine S.R. APL and the brain: treatment (abstract). Lupus 2002; 9: 559.</p><p>Ginsberg J.S., Wells P.S., Brill-Edwards P et al. Antiphospholipid antibodies and venous throm- boembolism. Blood 1995; 86: 3685-91.</p><p>Ames P.R.J., Ciampa A., Grandone E. et al. Conventional oral anticoagulation (INR 2-3) effectively prevents rethrombosis in primary antiphospholipid antibody syndrome (abstract). Lupus 2002; 9: 624.</p><p>Crowther M.A., Ginsberg J.S., Julian J. et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-8.</p><p>Finazzi G., Marchioli R., Brancaccio V. et al. A randomized clinical trial of high intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). Thromb Haemost 2005; 3: 848-53.</p><p>Kearon C., Gent M., Hirsh J. et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-7.</p><p>Hirsh J., Kearon C., Ginsberg J. Duration of anticoagulant therapy after first episode of venous thrombosis in patients with inherited thrombophilia. Arch Intern Med 1997;157: 2174-7.</p><p>Palareti G., Leali N., Cocheri S. et al. Bleeding complications of oral anticoagulant treatment: an inception - cohort, prospective collaborative study (ISCOAT). Italian study on complications of oral anticoagulant therapy. Lancet 1996; 348: 423-8.</p><p>Landefeld C.S., Beyth R.J. Anticoagulant - related bleeding: clinical epidemiology, prediction. Am J Med 1993;95: 315-28. Van der Meer F.J., Rosendaal F.R., Vandenbroucke J.P., Briet E. Bleeding complications in oral anticoagulant therapy. An analisis of risk factors. Arch Intern Med. 1993; 153: 1557-62.</p><p>McCrae K.R. Antiphospholipid antibody associated thrombosis: a consensus for treatment. Lupus 1996; 5: 560-70.</p><p>Giron-Gonzales J.A.,Garcia del Rio E., Rodriguez C. et al. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody procpectiva analysis of 404 individuals. J Rheumtol 2004; 31: 1560-7.</p><p>Решетняк Т.М., Кондратьева Л.В., Патрушев Н.Л. и др. Варфарин при лечении антифосфолипидного синдрома. Тер арх 2007;5: 47-54.</p><p>Кондратьева Л.В., Решетняк Т.М., Патрушева Н.Л. и др. Влияние полиморфизма цитохрома Р450 на эффективность и безопасность терапии варфарином у пациентов с антифосфолипидным синдромом. Научно-практ ревматол 2006; 4:63-9.</p><p>Beyth R.J., Quinn L., Landefeld C.S. A multi-component intervention to prevent major bleeding complications in older patients receiving warfarin: a randomized, controlled trial. Ann Intern Med 2000; 133: 687-95.</p></div><br />


Для цитирования:


Решетняк Т.М., Kondrat'eva L.V., Штивельбанд И.В., Насонов Е.Л. Варфарин в терапии антифосфолипидного синдрома. Современная ревматология. 2008;2(2):20-31. https://doi.org/10.14412/1996-7012-2008-469

For citation:


Reshetnyak T.M., Kondrat'eva L.V., Shtivel'band I.B., Nasonov E.L. Varfarin v terapii antifosfolipidnogo sindroma. Modern Rheumatology Journal. 2008;2(2):20-31. (In Russ.) https://doi.org/10.14412/1996-7012-2008-469

Просмотров: 870


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)